Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
      B7-H1 Antigen*/metabolism ; B7-H1 Antigen*/genetics ; Uterine Cervical Neoplasms*/genetics ; Uterine Cervical Neoplasms*/pathology ; Uterine Cervical Neoplasms*/metabolism ; Adenocarcinoma*/genetics ; Adenocarcinoma*/metabolism ; Adenocarcinoma*/pathology ; Epithelial-Mesenchymal Transition*/genetics ; Disease Progression* ; Antigens, Neoplasm*/genetics ; Antigens, Neoplasm*/metabolism ; Cell Proliferation*/genetics; Humans ; Female ; Middle Aged ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Cell Movement/genetics ; Up-Regulation ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/genetics ; Prognosis ; Adult
    • نبذة مختصرة :
      CT83, a cancer-testis antigen, has emerged as a potential biomarker and therapeutic target in various cancers. This study explores its expression and role in cervical adenocarcinoma progression and prognosis. CT83 expression was analyzed in cervical cancer cell lines using quantitative PCR and Western blotting. Functional assays demonstrated that CT83 overexpression (OE) promotes proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in cervical cancer cells while also upregulating PD-L1 expression. Conversely, CT83 knockdown reduced these malignant phenotypes. The immunohistochemical analysis of 60 patient samples revealed CT83 expression in 84.9% of cases, with significant correlations to larger tumor size, elevated squamous cell carcinoma antigen (SCC) levels, and advanced FIGO stages (II-IV). Furthermore, intermediate-to-high CT83 expression (H-score ≥100) was associated with more aggressive disease features. These findings suggest that CT83 contributes to tumor progression and immune evasion, likely through PD-L1 modulation. As a highly expressed antigen in cervical adenocarcinoma, CT83 offers promise as a diagnostic marker and therapeutic target for improving patient outcomes.
    • References:
      Immunol Rev. 2002 Oct;188:22-32. (PMID: 12445278)
      J Transl Med. 2024 Feb 7;22(1):141. (PMID: 38326843)
      J Cell Mol Med. 2021 Nov;25(22):10376-10388. (PMID: 34612587)
      Mod Pathol. 2014 Dec;27(12):1559-67. (PMID: 24762548)
      Cancer Manag Res. 2019 May 17;11:4597-4605. (PMID: 31191020)
      J Clin Oncol. 2019 Jun 10;37(17):1470-1478. (PMID: 30943124)
      BMC Cancer. 2022 Jul 30;22(1):834. (PMID: 35907786)
      Cell Prolif. 2019 May;52(3):e12581. (PMID: 30895661)
      J Immunother Cancer. 2023 May;11(5):. (PMID: 37137552)
      Anticancer Res. 2018 Oct;38(10):5923-5928. (PMID: 30275220)
      Science. 2017 Apr 14;356(6334):200-205. (PMID: 28408606)
      BMC Cancer. 2021 Mar 12;21(1):267. (PMID: 33711953)
      N Engl J Med. 2021 Nov 11;385(20):1856-1867. (PMID: 34534429)
      Arch Iran Med. 2009 Jul;12(4):395-404. (PMID: 19566358)
      J Clin Oncol. 2022 Mar 1;40(7):752-761. (PMID: 34990208)
      Front Pharmacol. 2018 May 22;9:536. (PMID: 29910728)
      Oncotarget. 2015 Jun 30;6(18):15772-87. (PMID: 26158218)
      Immunol Invest. 2016 Oct;45(7):619-40. (PMID: 27603913)
      Sci Rep. 2018 Apr 17;8(1):6131. (PMID: 29666402)
      Trends Cancer. 2018 Oct;4(10):701-712. (PMID: 30292353)
      CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
      Lancet Glob Health. 2023 Feb;11(2):e197-e206. (PMID: 36528031)
      Front Immunol. 2020 Dec 17;11:596825. (PMID: 33424844)
      Am J Surg Pathol. 2021 Jun 1;45(6):742-752. (PMID: 33298732)
      Gynecol Oncol. 2014 Nov;135(2):208-12. (PMID: 25152438)
      J Cancer Res Clin Oncol. 2023 Oct;149(13):11397-11410. (PMID: 37378674)
      J Immunother Cancer. 2019 Aug 28;7(1):229. (PMID: 31455429)
    • Grant Information:
      HURF-2022-44 Hallym University Dongtan Sacred Heart Hospital
    • Contributed Indexing:
      Keywords: CT83; PDL1; adenocarcinoma; cervix cancer
    • الرقم المعرف:
      0 (B7-H1 Antigen)
      0 (CD274 protein, human)
      0 (Antigens, Neoplasm)
      0 (Biomarkers, Tumor)
    • الموضوع:
      Date Created: 20250327 Date Completed: 20250327 Latest Revision: 20250329
    • الموضوع:
      20250329
    • الرقم المعرف:
      PMC11942592
    • الرقم المعرف:
      10.3390/ijms26062687
    • الرقم المعرف:
      40141328